Maftivimab
Based on 1 Customer Validation
Maftivimab (REGN3470-3471-3479) is a human monoclonal antibody targeting the glycoprotein of Zaire ebolavirus (ZEBOV), with an IC50 of 0.17 nM and a Kd of 2.97 nM. Maftivimab is applicable to research related to Zaire ebolavirus infection and Ebola virus disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 96.89%
- No. CAS: 2135632-36-7
- Peso molecular:143.94 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Human IgG1 kappa
Virus
|
ZEBOV 2.97 nM (Kd) |
ZEBOV 0.17 nM (IC50) |
Maftivimab binds with high affinity to the recombinant histidine-tagged extracellular domain protein of Ebola virus Makona strain glycoprotein (Kd = 2.97 × 10 nM[1]).
Maftivimab potently neutralizes Ebola pseudovirus particles in vitro, with an IC50 of 0.17 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
911829 [NCBI]
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 2135632-36-7
-
Appearance Liquid
-
Peso molecular 143.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Maftivimab]
-
Synonyms
REGN3470-3471-3479
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Markham A. REGN-EB3: First Approval. Drugs. 2021 Jan;81(1):175-178.
[2]. Gaudinski MR, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Maftivimab Related Classifications
HY-P99722 Related Classifications
Powered by Bioz